DB:TN72

Stock Analysis Report

Executive Summary

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases.

Snowflake

Fundamentals

Limited growth with imperfect balance sheet.

Risks

  • Titan Pharmaceuticals has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Titan Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.6%

DB:TN72

5.7%

DE Pharmaceuticals

3.2%

DE Market


1 Year Return

-89.5%

DB:TN72

-8.6%

DE Pharmaceuticals

-9.7%

DE Market

TN72 underperformed the Pharmaceuticals industry which returned -8.6% over the past year.

TN72 underperformed the Market in Germany which returned -9.7% over the past year.


Share holder returns

TN72IndustryMarket
7 Day3.6%5.7%3.2%
30 Day-60.0%5.8%-4.4%
90 Day-67.6%14.7%-2.0%
1 Year-89.5%-89.5%-5.5%-8.6%-6.9%-9.7%
3 Year-98.6%-98.6%-9.2%-17.0%11.8%2.2%
5 Yearn/a33.0%11.1%26.9%9.5%

Price Volatility Vs. Market

How volatile is Titan Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Titan Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Titan Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Titan Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of TN72’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Titan Pharmaceuticals regulatory filings.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Titan Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

0.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Titan Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.

Titan Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.

Titan Pharmaceuticals's revenue growth is expected to exceed the Germany market average.

Unable to compare Titan Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Titan Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Titan Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Titan Pharmaceuticals performed over the past 5 years?

-23.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Titan Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Titan Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Titan Pharmaceuticals's 1-year growth to the DE Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Titan Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Titan Pharmaceuticals has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Titan Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Titan Pharmaceuticals's financial position?


Financial Position Analysis

Titan Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Titan Pharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Titan Pharmaceuticals has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Titan Pharmaceuticals's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

Titan Pharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Titan Pharmaceuticals has less than a year of cash runway based on current free cash flow.

Titan Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 73.9% each year.


Next Steps

Dividend

What is Titan Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Titan Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Titan Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Titan Pharmaceuticals has not reported any payouts.

Unable to verify if Titan Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Titan Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Titan Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

1.0yrs

Average management tenure


CEO

Sunil Bhonsle (69yo)

3.8yrs

Tenure

US$520,079

Compensation

Mr. Sunil Bhonsle, M.B.A., has been the Chief Executive Officer of Titan Pharmaceuticals, Inc. since November 2015 and serves as its Principal Financial Officer. Mr. Bhonsle has been the President of Titan ...


CEO Compensation Analysis

Sunil's remuneration is higher than average for companies of similar size in Germany.

Sunil's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.0yrs

Average Tenure

61yo

Average Age

The average tenure for the Titan Pharmaceuticals management team is less than 2 years, this suggests a new team.


Board Age and Tenure

4.8yrs

Average Tenure

66.5yo

Average Age

The tenure for the Titan Pharmaceuticals board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$17,02225 Sep 18
M. MacFarlane
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares13,333.33
Max PriceUS$1.28
BuyUS$63,83225 Sep 18
Sunil Bhonsle
EntityIndividual
Role
Chief Executive Officer
President
Shares49,999.98
Max PriceUS$1.28
BuyUS$42,55525 Sep 18
James McNab
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares33,333.32
Max PriceUS$1.28
BuyUS$85,11025 Sep 18
Marc Rubin
EntityIndividual
Role
Chairman of the Board
Executive Chairman of the Board
Shares66,666.64
Max PriceUS$1.28
BuyUS$42,55525 Sep 18
Joseph Akers
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares33,333.32
Max PriceUS$1.28

Ownership Breakdown


Management Team

  • Sunil Bhonsle (69yo)

    President

    • Tenure: 3.8yrs
    • Compensation: US$520.08k
  • Marc Rubin (64yo)

    Executive Chairman of the Board

    • Tenure: 10.3yrs
    • Compensation: US$420.08k
  • Kate Beebe-DeVarney (58yo)

    Executive VP & Chief Scientific Officer

    • Tenure: 1.0yrs
  • Brian Crowley

    Vice President of Finance

    • Tenure: 0.0yrs
  • Dane Hallberg (50yo)

    Executive VP & Chief Commercial Officer

    • Tenure: 0.8yrs
  • Jennifer Kiernan

    Executive Assistant to CEO & Investor Communications Coordinator

    • Tenure: 0.0yrs

Board Members

  • Sunil Bhonsle (69yo)

    President

    • Tenure: 3.8yrs
    • Compensation: US$520.08k
  • Jim McNab (75yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: US$57.50k
  • M. MacFarlane (78yo)

    Independent Director

    • Tenure: 17.3yrs
    • Compensation: US$60.00k
  • Marc Rubin (64yo)

    Executive Chairman of the Board

    • Tenure: 10.3yrs
    • Compensation: US$420.08k
  • Joe Akers (73yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: US$57.50k
  • Rajinder Kumar (64yo)

    Director

    • Tenure: 2.6yrs
    • Compensation: US$50.00k
  • Scott Smith (57yo)

    Director

    • Tenure: 2.6yrs
    • Compensation: US$52.50k
  • Federico Recli (49yo)

    Lead Director

    • Tenure: 1.3yrs
    • Compensation: US$31.37k

Company Information

Titan Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Titan Pharmaceuticals, Inc.
  • Ticker: TN72
  • Exchange: DB
  • Founded: 1992
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$6.966m
  • Listing Market Cap: US$6.253m
  • Shares outstanding: 15.74m
  • Website: https://www.titanpharm.com

Number of Employees


Location

  • Titan Pharmaceuticals, Inc.
  • 400 Oyster Point Boulevard
  • Suite 505
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TTNPNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 1996
TN72DB (Deutsche Boerse AG)YesCommon StockDEEURJan 1996

Biography

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform th ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/23 20:40
End of Day Share Price2019/08/23 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.